URGN UroGen Pharma Ltd.

URGN financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1668243 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 4, 2026 Data checked: Nov 10, 2026
Showing 3 of 11 annual and 0 of 35 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$620.40M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
L3
Fiscal Year End
December (1231)
Phone
972 9 770 7601
EIN
000000000
Headquarters
RA'ANANA, L3, 4365007
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$250.25M
Net Income
$-65.75M
Total Assets
$271.87M
Total Equity
$-125.22M
Total Debt
-
Free Cash Flow
$-132.05M
Ratios
Gross Margin
91.4%
Operating Margin
-12.4%
Net Margin
-26.3%
Return on Equity
52.5%
Return on Assets
-24.2%
Current Ratio
3.4x
FCF / Assets
-48.6%

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

UroGen Pharma Ltd. generated $109.79M of revenue in fiscal 2025, with net loss of $153.49M and an operating cash outflow of $162.44M. At $109.79M, the top line establishes the operating scale supporting the company’s profit and cash-flow profile. The top line expanded 21.4% from $90.40M in fiscal 2024, increasing the company’s operating scale. At period end, total assets were $200.46M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.55x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

After reported cost of revenue, the company retained $97.34M as gross profit before recognizing operating expenses and other items. Gross profit represented 88.7% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $124.86M, reflecting costs that exceeded gross profit. An operating margin of -113.7% reflected costs exceeding revenue-level gross profit by 113.7% of sales. The company ended the period with a net loss of $153.49M, extending the operating result through all remaining items. The net loss equaled 139.8% of revenue, showing the bottom-line deficit relative to the company’s sales base. The company reported negative EBITDA of $124.56M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The company reported a pretax loss of $153.42M, before the effect of income taxes. Measured against revenue, the pretax deficit represented 139.7%. The company recognized $78.00K of income tax for the period, completing the transition from pretax income to net income. The net loss equaled 76.6% of period-end assets, showing the deficit relative to the asset base. Compared with a $126.87M net loss in fiscal 2024, the current loss increased to $153.49M.

Liquidity and Capital Structure

Total assets were $200.46M, supported by $305.93M of liabilities and -$105.47M of shareholder equity. The company reported negative equity of -$105.47M, a capital deficit that reduces its ability to absorb losses through book equity. The near-term balance sheet paired $186.02M of current assets with $46.42M of current liabilities at the reporting date. Current assets covered current liabilities by 4.01x, leaving a positive buffer for near-term obligations. Reported cash and equivalents were $110.75M, separating immediately recognizable cash resources from the rest of the current-asset base. Measured only with cash and equivalents, coverage of current liabilities was 238.6%, excluding receivables and other current assets. Borrowings totaled $122.21M, adding a fixed financing obligation alongside the company’s equity capital. The debt-to-assets relationship was 61.0%, comparing borrowing with the total asset balance. The equity-to-assets relationship was -52.6%, placing book capital against the total resource base. Relative to total assets, liabilities measured 152.6%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 55.2% of total assets, showing the liquid cash component within the company’s broader resource base. Compared with $285.71M in fiscal 2024, the current asset base moved 29.8% and finished lower. The reported cash balance changed 35.6% from $171.99M in fiscal 2024, ending lower year over year.

Cash Flow and Earnings Quality

Operating activities used $162.44M of cash, resulting in an operating cash outflow for the year. Capital spending of $289.00K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Operating cash flow and capital spending combined to leave a $162.73M cash deficit after capital spending. Free-cash-flow margin was -148.2%, reflecting a cash deficit equal to 148.2% of revenue after capital spending. Relative to total assets, the post-investment cash deficit measured 81.2%. The operating cash outflow widened to $162.44M from $96.77M in fiscal 2024.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for UroGen Pharma Ltd.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $109.79M $90.40M $82.71M
Cost of Revenue $12.45M $8.88M $9.36M
Gross Profit $97.34M $81.52M $73.35M
OPERATING EXPENSES
R&D Expense $67.11M $57.15M $45.61M
SG&A Expense $155.10M $121.15M $93.27M
Other Operating Expenses (derived) $0 $0 $0
Operating Income $-124.86M $-96.78M $-65.54M
NON-OPERATING INCOME / EXPENSE
Interest Income $5.97M $8.90M $2.64M
Other Income/Expense $-670.00K $-229.00K $838.00K
Pretax Income $-153.42M $-124.04M $-98.32M
Income Tax $78.00K $2.83M $3.92M
Net Income $-153.49M $-126.87M $-102.24M
PER SHARE & SUPPLEMENTAL
EBITDA $-124.56M $-96.45M $-64.73M
Depreciation & Amortization $307.00K $329.00K $802.00K
Balance Sheet
ASSETS
Cash & Equivalents $110.75M $171.99M $95.00M
Short-term Investments $49.31M $110.67M $56.16M
Accounts Receivable $33.08M $20.30M $15.44M
Inventory $16.46M $9.23M $5.67M
Other Current Assets $14.67M $8.85M $10.28M
Current Assets $186.02M $276.14M $169.19M
PP&E (Net) $637.00K $655.00K $689.00K
Other Noncurrent Assets $5.16M $589.00K $2.04M
Noncurrent Assets $14.43M $9.58M $9.13M
Total Assets $200.46M $285.71M $178.31M
LIABILITIES
Accounts Payable $12.14M $10.93M $6.51M
Other Current Liabilities $5.19M $7.95M $3.86M
Current Liabilities $46.42M $45.95M $31.21M
Long-term Debt $122.21M $121.73M $98.55M
Other Noncurrent Liabilities (derived) $137.30M $126.83M $113.76M
Noncurrent Liabilities $259.51M $248.57M $212.31M
Total Liabilities $305.93M $294.51M $243.52M
EQUITY
Common Stock $133.00K $115.00K $89.00K
Additional Paid-in Capital $854.09M $797.25M $614.04M
Retained Earnings $-959.72M $-806.22M $-679.35M
Accumulated OCI $19.00K $56.00K $12.00K
Total Equity $-105.47M $-8.80M $-65.21M
Total Liabilities & Equity $200.46M $285.71M $178.31M
SUPPLEMENTAL
Shares Outstanding 48.35M 42.23M 32.49M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-162.44M $-96.77M $-76.38M
Capital Expenditures $289.00K $295.00K $194.00K
Cash from Investing $61.56M $-20.61M $-953.00K
Cash from Financing $39.92M $194.62M $116.93M
Free Cash Flow $-162.73M $-97.06M $-76.57M
Beginning Cash (CFS) $173.06M $95.82M $56.22M
Net Change in Cash $-60.97M $77.24M $39.60M
Effect of FX on Cash - - -
Calculated Ending Cash $112.10M $173.06M $95.82M
Cash per BS $110.75M $171.99M $95.00M
Cash scope difference (CFS − BS) $1.35M $1.08M $821.00K
Cash per CFS $112.10M $173.06M $95.82M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is UroGen Pharma Ltd.'s annual revenue?

UroGen Pharma Ltd. reported $250.25M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is UroGen Pharma Ltd. profitable?

No. UroGen Pharma Ltd. reported $-65.75M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.

Does UroGen Pharma Ltd. generate free cash flow?

No. Free cash flow was $-132.05M for trailing twelve months. Operating cash flow was $-131.85M.